Published in Eur J Cancer on June 08, 2010
A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre. Ther Adv Med Oncol (2012) 0.95
Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy-a representative sample survey in Germany. Support Care Cancer (2015) 0.88
Use of a German longitudinal prescription database (LRx) in pharmacoepidemiology. Ger Med Sci (2015) 0.80
Neutropenia and G-CSF in lymphoproliferative diseases. Hematology (2012) 0.79
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study. Ther Clin Risk Manag (2013) 0.78
Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen. Support Care Cancer (2014) 0.75
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer (2017) 0.75
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol (2003) 2.87
[Spiruline as a food supplement in case of infant malnutrition in Burkina-Faso]. Arch Pediatr (2003) 2.78
Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol (2003) 2.07
An assessment of the California Child Passenger Restraint Requirement. Am J Public Health (1985) 1.97
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol (2012) 1.62
Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg (2004) 1.59
Brown fat in breast cancer patients: analysis of serial (18)F-FDG PET/CT scans. Eur J Nucl Med Mol Imaging (2006) 1.53
Structural sequences are conserved in the genes coding for the alpha, alpha' and beta-subunits of the soybean 7S seed storage protein. Nucleic Acids Res (1982) 1.52
The isolation and partial characterization of recombinant DNA containing genomic globin sequences from the goat. J Biol Chem (1979) 1.44
Superficial angiomyxoma: clinicopathologic analysis of a series of distinctive but poorly recognized cutaneous tumors with tendency for recurrence. Am J Surg Pathol (1999) 1.30
Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immunol Methods (2007) 1.29
Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol (1996) 1.27
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol (2009) 1.26
Hypoxia and the malignant glioma microenvironment: regulation and implications for therapy. Curr Mol Pharmacol (2009) 1.21
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer (2009) 1.14
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol (2007) 1.14
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer (2011) 1.13
Quality of final care for terminal cancer patients in a comprehensive cancer centre from the point of view of patients' families. Support Care Cancer (1996) 1.12
Altered systemic iron metabolism in Parkinson's disease. Neurology (1997) 1.11
Rhabdomyosarcoma arising in mediastinal teratoma in an adult man: a case report. Ann Oncol (2002) 1.10
Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol (2003) 1.10
Detection of QTL for milk production traits in cattle by application of a specifically developed marker map of BTA6. Anim Genet (1999) 1.08
Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. Ann Oncol (2009) 1.05
Self assembled monolayers on silicon for molecular electronics. Anal Chim Acta (2005) 1.02
Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol (2004) 1.01
Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. Ann Oncol (2012) 0.98
Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria. Br J Radiol (2002) 0.98
Validation of UBE2C protein as a prognostic marker in node-positive breast cancer. Br J Cancer (2009) 0.97
Dietary iron, animal fats, and risk of Parkinson's disease. Mov Disord (1998) 0.96
Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer (2008) 0.95
Prognostic impact of the expression/phosphorylation of the BH3-only proteins of the BCL-2 family in glioblastoma multiforme. Cell Death Dis (2012) 0.95
Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. Eur J Cancer (2012) 0.95
Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann Oncol (2001) 0.95
Validity of Minnesota Child Development Inventory in screening young children's developmental status. J Pediatr Psychol (1984) 0.94
Genetic heterogeneity of early-onset familial breast cancer. Hum Genet (1992) 0.93
Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Ann Oncol (2004) 0.92
[Granulosa cell tumour: review of the literature]. Bull Cancer (2000) 0.91
Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours. Eur J Cancer (2009) 0.91
Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? Int J Hematol (2010) 0.91
Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial. Ann Oncol (2013) 0.91
Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'. Ann Oncol (2005) 0.90
Quantification of docetaxel and its main metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2005) 0.90
Visceral leishmaniasis. Persistence of parasites in lymph nodes after clinical cure. J Infect (2003) 0.89
A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment. Ann Oncol (2014) 0.88
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Res Treat (2008) 0.88
Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial. Ann Oncol (2013) 0.88
Differential regulation of activation, clonal expansion, and antibody secretion in human B cells. J Immunol (1985) 0.87
A dynamic model of hand-and-foot syndrome in patients receiving capecitabine. Clin Pharmacol Ther (2008) 0.87
Cloning, expression and sequencing the molybdenum-pterin binding protein (mop) gene of Clostridium pasteurianum in Escherichia coli. Nucleic Acids Res (1986) 0.86
Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. J Neurooncol (2013) 0.86
Oral vinorelbine: feasibility and safety profile. Ann Oncol (2001) 0.86
Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. Br J Cancer (2011) 0.85
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur J Cancer (2002) 0.85
Recent trends in breast cancer incidence rates in the Loire-Atlantique, France: a decline since 2003. Cancer Epidemiol (2010) 0.85
Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy. Ann Oncol (2010) 0.85
Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias. Ann Oncol (2010) 0.85
A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels. Ann Oncol (2000) 0.85
Hyperthermia to normal human skin in vivo upregulates heat shock proteins 27, 60, 72i and 90. J Cutan Pathol (2000) 0.84
Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial. Eur J Cancer (2013) 0.84
Quantitative prognostic indices in peritoneal carcinomatosis. Eur J Surg Oncol (2006) 0.84
Electrophoretic mobility of blood lymphocytes in cancer patients. Biomedicine (1975) 0.84
Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group. Ann Oncol (2011) 0.83
Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Ann Oncol (2000) 0.83
An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics. J Pharmacokinet Pharmacodyn (2008) 0.83
Surgical management of Dupuytren's contracture in Europe: regional analysis of a surgeon survey and patient chart review. Int J Clin Pract (2013) 0.83
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann Oncol (2002) 0.83
Any clinical benefit from the use of oncofoetal markers in the management of chemotherapy for patients with metastatic colorectal carcinomas? Clin Oncol (R Coll Radiol) (2004) 0.82
EPICC study: evaluation of pharmaceutical intervention in cancer care. J Clin Pharm Ther (2015) 0.82
[Prognostic and predictive factors for gliomas in adults]. Bull Cancer (2009) 0.82
The influence of fibril composition and dimension on the performance of paper gated oxide transistors. Nanotechnology (2014) 0.81
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. Br J Cancer (2012) 0.81
Use of liposomal doxorubicin-cyclophosphamide combination in breast cancer patients with brain metastases: a monocentric retrospective study. J Neurooncol (2014) 0.80
Characterization of the human mitochondrial aconitase gene (ACO2). Gene (1998) 0.80
Chemotherapy may be delivered based on an integrated view of tumour dynamics. IET Syst Biol (2009) 0.79
[Is geriatric assessment adapted to radiotherapy?]. Cancer Radiother (2008) 0.79
Dupuytren's disease presentation, referral pathways and resource utilisation in Europe: regional analysis of a surgeon survey and patient chart review. Int J Clin Pract (2013) 0.79
[Production of O antigens and antibodies during urinary tract infections due to Escherichia coli (author's transl)]. Nouv Presse Med (1979) 0.78
Is there a genetic susceptibility locus for Parkinson's disease on chromosome 22q13? Ann Neurol (1997) 0.78
Electron transport through rectifying self-assembled monolayer diodes on silicon: Fermi-level pinning at the molecule-metal interface. J Phys Chem B (2006) 0.78
Lichen planus-like eruption following autologous bone marrow transplantation for chronic myeloid leukaemia. Australas J Dermatol (2001) 0.78
Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements. Br J Cancer (2013) 0.78
Drug-resistant Mycobacterium tuberculosis strains in tuberculosis inpatients in Bangui, Central African Republic. AIDS (1995) 0.78
A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients. Cancer Chemother Pharmacol (1999) 0.78
Modelling of ftorafur and 5-fluorouracil pharmacokinetics following oral UFT administration. A population study in 30 patients with advanced breast cancer. Cancer Chemother Pharmacol (2003) 0.77
[Advantage of using tumor markers in colorectal and breast cancers. Guidelines of the American Society of Clinical Oncology (ASCO)]. Bull Cancer (1997) 0.77
Concurrent validity of the Minnesota Child Development Inventory in a nonclinical sample. J Consult Clin Psychol (1983) 0.77
Trends in tobacco smoking among adolescents in Lyon, France. Eur J Cancer (2003) 0.77
Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial. Clin Oncol (R Coll Radiol) (2008) 0.76
Population pharmacokinetics of short intravenous vinorelbine infusions in patients with metastatic breast cancer. Cancer Chemother Pharmacol (2003) 0.76
Lapatinib in metastatic breast cancer. Womens Health (Lond Engl) (2009) 0.76
Persistent decrease in proliferative potential of marrow CD34(+)cells exposed to early-acting growth factors after autologous bone marrow transplantation. Bone Marrow Transplant (2002) 0.76
Endometrial mesodermal mixed tumor occurring after tamoxifen treatment: report on a new case and review of the literature. Ann Oncol (2000) 0.76
In-vitro cytotoxic activity of cross-linked protein microcapsules. J Pharm Pharmacol (1986) 0.76
Minnesota Child Development Inventories: predictors of intelligence, achievement, and adaptability. J Pediatr Psychol (1987) 0.75
[Association of Steinert's disease and testicular cancer]. Presse Med (1987) 0.75
[Implications of receptors for the Fc portion of IgG (FcgammaRs) in mechanism of action of therapeutic antibodies]. Bull Cancer (2010) 0.75